These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 29039233)

  • 21. Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use.
    Walsh Z; Hendricks PS; Smith S; Kosson DS; Thiessen MS; Lucas P; Swogger MT
    J Psychopharmacol; 2016 Jul; 30(7):601-7. PubMed ID: 27097733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.
    Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR
    Ir J Med Sci; 2022 Jun; 191(3):1385-1397. PubMed ID: 34131812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.
    Mellner C; Dahlen M; Simonsson O
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychedelics not linked to mental health problems or suicidal behavior: a population study.
    Johansen PØ; Krebs TS
    J Psychopharmacol; 2015 Mar; 29(3):270-9. PubMed ID: 25744618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelic-Assisted Group Therapy: A Systematic Review.
    Trope A; Anderson BT; Hooker AR; Glick G; Stauffer C; Woolley JD
    J Psychoactive Drugs; 2019; 51(2):174-188. PubMed ID: 30950777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.
    Jones G; Arias D; Nock M
    Sci Rep; 2022 Dec; 12(1):21927. PubMed ID: 36535992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular insights into psychedelic drug action.
    Slocum ST; DiBerto JF; Roth BL
    J Neurochem; 2022 Jul; 162(1):24-38. PubMed ID: 34797943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
    Johnson MW
    Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.
    Simonsson O; Goldberg SB
    J Psychoactive Drugs; 2023; 55(1):11-18. PubMed ID: 35000559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in the Top-Cited Articles on Classic Psychedelics.
    Lawrence DW; Sharma B; Griffiths RR; Carhart-Harris R
    J Psychoactive Drugs; 2021; 53(4):283-298. PubMed ID: 33535907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations between lifetime classic psychedelic use and cardiometabolic diseases.
    Simonsson O; Osika W; Carhart-Harris R; Hendricks PS
    Sci Rep; 2021 Jul; 11(1):14427. PubMed ID: 34257396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The psychedelic effects of cannabis: A review of the literature.
    Wolinsky D; Barrett FS; Vandrey R
    J Psychopharmacol; 2024 Jan; 38(1):49-55. PubMed ID: 37947321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential.
    Rucker JJ
    BMJ; 2015 May; 350():h2902. PubMed ID: 26014506
    [No Abstract]   [Full Text] [Related]  

  • 39. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
    Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
    J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness.
    Forstmann M; Sagioglou C
    J Psychopharmacol; 2017 Aug; 31(8):975-988. PubMed ID: 28631526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.